3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
Cisplatin
117
Oxaliplatin
111
Fluorouracil
100
Capecitabine
90
Docetaxel
69
Leucovorin
60
Irinotecan
57
Paclitaxel
49
S 1 (combination)
38
pembrolizumab
35
Trastuzumab
31
Radiotherapy
25
Bevacizumab
20
Nivolumab
19
Epirubicin
19
titanium silicide
18
Surgical Procedures, Operative
17
Carboplatin
17
Ramucirumab
16
Cetuximab
15
Gastrectomy
13
apatinib
12
Everolimus
12
Gemcitabine
11
Albumin-Bound Paclitaxel
10
Neoadjuvant Therapy
8
Folfox protocol
8
Drug Therapy
8
Chemotherapy, Adjuvant
8
Radiation
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Stomach Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts